Detalles de la búsqueda
1.
Personalizing neoadjuvant chemotherapy for locally advanced colon cancer: protocols for the international phase III FOxTROT2 and FOxTROT3 randomized controlled trials.
Colorectal Dis
; 25(3): 357-366, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36710525
2.
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
Blood
; 136(9): 1091-1104, 2020 08 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-32438407
3.
Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma.
Br J Haematol
; 193(3): 551-555, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32524584
4.
Choice of HbA1c threshold for identifying individuals at high risk of type 2 diabetes and implications for diabetes prevention programmes: a cohort study.
BMC Med
; 19(1): 184, 2021 08 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-34412655
5.
DNA methylation and inflammation marker profiles associated with a history of depression.
Hum Mol Genet
; 27(16): 2840-2850, 2018 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29790996
6.
Long-term follow-up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide-based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors.
Am J Hematol
; 97(5): E168-E171, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35108412
7.
NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma.
EClinicalMedicine
; 60: 102015, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37287870
8.
Construct validation of the Research Engagement Survey Tool (REST).
Res Involv Engagem
; 8(1): 26, 2022 Jun 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-35710531
9.
NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC).
BMJ Open
; 10(2): e034527, 2020 02 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32029495
Resultados
1 -
9
de 9
1
Próxima >
>>